BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services


Ludiflash® is a combined filler, binder and disintegrant, designed to dissolve in the mouth within seconds.

Ludiflash® comprises the following ingredients: 90 percent Mannitol, a fast-dissolving filler with a mildly sweet taste; 5 percent Kollidon® CL-SF (crospovidone), a superior tablet disintegrant that is effective even with very little liquid; and 5 percent Kollicoat® SR 30 D (polyvinyl acetate), a hydrophobic binder. Each component complies with all leading pharmacopoeia monographs. Plus, the fast-disintegrating, fast-acting formulations created with Ludiflash® offer an exceptionally smooth and creamy mouthfeel – enhancing patient compliance.

Ludiflash® delivers tangible benefits to manufacturers, exhibiting good flowability, compressibility and stability. The compound’s low hygroscopicity ensures the stability of the active ingredient and of the tablet itself.

Ludiflash® is suitable for direct compression and roller compaction, and can be deployed in wet-granulation processes. Blends can be processed on standard tableting machines or used in the form of granulate or powder. When a standard tableting process is used, Ludiflash® ensures excellent uniformity, even at high speeds: creating compact and highly porous tablets that offer exceptional hardness and low friability, making them suitable for polyethylene containers and push-through blisters.

www.pharma-ingredients.basf.com/Ludiflash/Home.aspx

pharma-ingredients@basf.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here